Features associated with efficacy in BRAF or combined BRAF and MEK therapy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Degree of response and the duration of survival of patients treated with mitogen-activated protein kinase (MAPK) inhibitors are highly variable. A recent study found sex, serum LDH, BRAF genotype, and primary melanoma ulceration status to be independent factors associated with treatment outcomes. Patients with a complete response to treatment have the best survival, but relapses still occur.


  • Cohort: 142 consecutive immunotherapy- and MAPK inhibitor-naive patients with BRAF-mutant metastatic melanoma treated during clinical trials with BRAF inhibitors (n=111) or a combination of dabrafenib and trametinib (n=31)
  • Clinicopathologic factors were correlated with the response to MAPK inhibitors and survival


  • Median follow-up: ...